New genetic test may change how brain cancer is treated, researchers say

August 20, 2014 by Tiffany L Trent

(Medical Xpress)—Scientists at Virginia Tech's Virginia Bioinformatics Institute working with the Center for Cancer and Blood Disorders at Children's National Medical Center have found a new way to diagnose brain cancer based on genetic markers found in "junk DNA."

The finding, recently published in Oncotarget, could revolutionize the way doctors treat certain cancers.

Brain cancer is the second leading cancer-related cause of death in children. Overall, 70,000 new patients were diagnosed with primary in 2013, according to the American Brain Tumor Association.

However, only about a third turn out to be malignant. Ordinarily, when a patient shows symptoms of a brain tumor, an MRI is performed to locate tumors, but it cannot determine whether the tumor is benign or malignant, often necessitating costly and occasionally dangerous or inconclusive biopsies.

A simple blood test to detect could change all that.

"Patients with less aggressive types of cancer as determined by this test would not need a biopsy," said Harold 'Skip' Garner, a professor and director of the Medical Informatics and Systems Division at the Virginia Bioinformatics Institute. "The biopsy is expensive both medically and financially—one percent of patients die and seven percent have permanent neurological damage from the procedure, according to the Canadian Journal of Neurology. This finding may reduce costs and save lives."

Microsatellites, long dismissed as "junk DNA," comprise the one million DNA sequence repeats in the human genome.

Though they've been effective in identifying rare conditions such as Huntington's and Fragile X syndrome, next-generation genome sequencing is allowing researchers to find increasingly more markers for a variety of diseases, including and autism.

The study analyzed germline (blood) sequences from the National Institutes of Health 1000 Genomes Project and the Cancer Genome Atlas.

Analyzing the microsatellites from these sequences revealed that patients with various stages of glioma showed recognizable and consistent markers in their genomes for the disease.

This information indicates it is possible to develop a simple blood test that would help identify patients with different grades, which could reduce invasive and inconclusive brain biopsies.

These new, microsatellite-based diagnostics are applicable to many other cancers and diseases. It is hoped that with continued study, more markers and potential drug targets or therapies will be found.

To further the development of such diagnostics, Garner has founded Genomeon, which holds an exclusive license in microsatellite technologies worldwide. Michael B. Waitzkin, CEO of Genomeon, said, "A that can reliably differentiate between a malignant and benign brain tumor will have important clinical significance potentially preventing unnecessary brain biopsies which carry great risks to the patient and substantial costs to the health care system."

Explore further: Researchers discover new markers for breast cancer that may aid diagnoses, point to new therapies

More information: Karunasena, E., McIver, L., Rood, B., Wu, X., Zhu, H., Bavarva, J., & Garner, H. (2014). Somatic intronic microsatellite loci differentiate glioblastoma from lower-grade gliomas. Oncotarget, 5(14), 6003-6014. Retrieved from www.impactjournals.com/oncotar … view&path%5B%5D=2076

Related Stories

Researchers discover new markers for breast cancer that may aid diagnoses, point to new therapies

July 8, 2014
(Medical Xpress)—The fight against breast cancer is never-ending, but Virginia Tech researchers in the Medical Informatics and Systems Division at the Virginia Bioinformatics Institute have found additional diagnostic markers ...

Combo tumor imaging can distinguish malignant and benign breast tumors, help avoid biopsies

June 24, 2014
Imaging breast tumors using four approaches together can better distinguish malignant breast tumors from those that are benign, compared with imaging using fewer approaches, and this may help avoid repeat breast biopsies, ...

Aging contributes to rapid rates of genomic change, signaling challenges for personalized medicine

June 24, 2014
(Medical Xpress)—Exploiting individual genomes for personalized medicine may be more complicated than medical scientists have suspected, researchers at Virginia Bioinformatics Institute have discovered.

Metastatic brain tumor treatment could be on the horizon with use of SapC-DOPS

July 24, 2014
Over half of patients being seen in the clinic for a diagnosed brain tumor have metastatic cancer, which has no treatment and detrimental outcomes in most cases.

Researchers develop web-based app to predict glioma mutations

August 19, 2014
A new web-based program developed by University of Kentucky Markey Cancer Center researchers will provide a simple, free way for healthcare providers to determine which brain tumor cases require testing for a genetic mutation.

TGen, Scottsdale Healthcare begin study of new drug for patients with solid tumors

June 17, 2014
The Virginia G. Piper Cancer Center at Scottsdale Healthcare and the Translational Genomics Research Institute (TGen) are studying the safety and effectiveness of a new drug, AG-120, for treatment of patients with solid tumors, ...

Recommended for you

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.